Abstract: An optical system and a display apparatus are provided. The optical system includes: a lens component, a polarized reflection layer, a transflective film, and a phase retardation film; a distance between two intersection points where the first surface and the second surface intersect with the optical axis is a first distance, a distance between two intersection points where the third surface and the fourth surface intersect with the optical axis is a second distance, and a distance between two intersection points of the fifth surface and the sixth surface intersect with the optical axis is a third distance; a ratio of an absolute value of a curvature radius of the fourth surface to an absolute value of a curvature radius of the third surface is 0.8 to 1, the second distance is greater than the first distance, and the second distance is greater than the third distance.

Abstract: An optical structure and a display device are provided. The optical structure includes a first lens and a transflective film. The first lens includes a first surface and a second surface, the first surface and the second surface are non-planar surfaces; the transflective film is located at a side of the first surface away from the second surface. The optical structure further includes a light-transmitting flat plate assembly located at a side of the second surface away from the first surface, and the light-transmitting flat plate assembly includes a light-transmitting flat plate, a phase retardation film and a polarizing reflective film, the polarizing reflective film is located at a side of the phase retardation film away from the first lens, and the phase retardation film and the polarizing reflective film are located on a flat plate surface of the light-transmitting flat plate or inside the light-transmitting flat plate.

Abstract: The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as siRNAs, able to Inhibin Subunit Beta E (INHBE) gene expression. Also disclosed are pharmaceutical compositions that include INHBE RNAi agents and methods of use thereof. The INHBE RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the INHBE RNAi agents in vivo provides for inhibition of INHBE gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by INHBE gene expression, such as obesity, diabetes, liver inflammation, dyslipidemia, or metabolic disease.

Abstract: The present disclosure provides an optical polarizing device and a manufacturing method therefor, and a near-eye display apparatus. The optical polarizing device includes: a reflective polarizing film, a linear polarizing coating located on one side of the reflective polarizing film, and a phase retardation coating located on the other side of the reflective polarizing film. A distance between at least one of the linear polarizing coating and the phase retardation coating and a surface of the reflective polarizing film is less than 0.5 micrometers.

Abstract: The present disclosure relates to RNAi agents, for example, double stranded RNAi agents, able to inhibit HIF-2 alpha (EPAS1) gene expression. Also disclosed are pharmaceutical compositions that include HIF-2 alpha RNAi agents and methods of use thereof. The HIF-2 alpha RNAi agents disclosed herein may be linked or conjugated to targeting ligands (such as compounds that have affinity for integrins, including alpha-v-beta-3 and alpha-v-beta-5 integrins) and pharmacokinetic (PK) enhancers, to facilitate the delivery to cells and tissues, including to clear cell renal cell carcinoma (ccRCC) cells and tumors. Delivery of compositions comprising the HIF-2 alpha RNAi agents in vivo provides for inhibition of HIF-2 alpha gene expression. The HIF-2 alpha RNAi agents can be used in methods of treatment of various diseases and disorders, including ccRCC.

Abstract: The disclosure provides a method for an electronic device including a lens; a plurality of light sources disposed on or adjacent to an edge of the lens, and configured to illuminate an eye of a user; at least one camera disposed adjacent to the edge of the lens, and configured to capture an image of the eye; and a controller configured to perform eye tracking for the user based on the image captured by the at least one camera. According to the embodiments of the disclosure, on a premise that the characteristics of the lens are not affected by the electronic device, a feasibility of capturing the eye image and quality of the image are ensured.

Abstract: A head-mounted display device and a control method thereof, and a computer-readable storage medium are provided. The head-mounted display device includes a display screen and a lens component, and the control method of the head-mounted display device includes: determining gaze directions of both eyes of a user; determining a gaze focus according to the gaze directions of the both eyes; and adjusting positions of the display screen and the lens component according to the gaze focus, so that the gaze focus is located at an image plane position of a virtual image formed by the lens component from an image displayed by the display screen.

Abstract: The present invention provides a diffractive optical waveguide and a preparation method thereof, and an augmented reality display device. The diffractive optical waveguide includes: a total reflection layer, wherein the total reflection layer includes a first light propagation layer and a second light propagation layer, which are disposed in a stacked manner, a refractive index of the second light propagation layer is less than a refractive index of the first light propagation layer, and the second light propagation layer is deposited on one surface of the first light propagation layer via a deposition method; and a coupling-in grating and a coupling-out grating, wherein the coupling-in grating and the coupling-out grating are disposed at intervals on a side of the first light propagation layer that faces away from the second light propagation layer.

Abstract: A system such as a vehicle, building, or electronic device system may have a support structure with one or more windows. The support structure and window may separate an interior region within the system from a surrounding exterior region. Control circuitry may receive input such as user input and may adjust an adjustable layer in the window based on the input. The adjustable layer may be an adjustable light transmission layer. The adjustable light transmission layer may have a polymer matrix layer with embedded guest-host liquid crystal cells. Each cell may have liquid crystal material and dichroic dye. The adjustable light transmission layer may be operated in a dark state to prevent light from passing through the window, a clear state in which the window passes light, and intermediate states that exhibit intermediate light transmission levels.

Abstract: A system such as a vehicle, building, or electronic device system may have a support structure with one or more windows. The support structure and window may separate an interior region within the system from a surrounding exterior region. Control circuitry may receive input such as user input and may adjust an adjustable layer in the window based on the input. The adjustable layer may have a polymer matrix layer with embedded cells. The cells may include intermixed guest-host liquid crystal cells and liquid crystal cells. The guest-host liquid crystal cells and liquid crystal cells may have different liquid crystal materials and/or different sizes that allow the guest-host liquid crystal cells and liquid crystal cells to electrically switch states at different respective threshold voltages. Based on the user input or other input the control circuitry can adjust a drive signal across the adjustable layer to change light transmittance and haze.

Abstract: According to embodiments of the disclosure, a method, apparatus, device, and storage medium for image processing are provided. In this method, an image sensing unit array of a camera is divided into a set of full processing units and at least one set of partial processing units based on a characteristic of a lens of the camera, and/or a current gazing point of a user of the camera. Within at least one stage of a plurality of stages of an imaging process using the camera, a processing load associated with at least some units of the partial processing units is reduced.

Abstract: The present disclosure relates to delivery platforms that specifically and efficiently direct payloads to skeletal muscle cells in a subject, in vivo. The delivery platforms disclosed herein include targeting ligands (such as compounds that have affinity for integrins, including alpha-v-beta-6) and pharmacokinetic/pharmacodynamic (PK/PD) modulators, to facilitate the delivery of payloads to cells, including to skeletal muscle cells. Suitable payloads for use in the delivery platforms disclosed herein include RNAi agents, which can be linked or conjugated to the delivery platforms, and when delivered in vivo, provide for the inhibition of gene expression in skeletal muscle cells. Pharmaceutical compositions that include the skeletal muscle cell delivery platform are also described, as well as methods of use for the treatment of various diseases and disorders where delivery of a therapeutic payload to a skeletal muscle cell is desirable.

Abstract: A display may include illumination optics, a ferroelectric liquid crystal on silicon (fLCOS) panel, and a waveguide. The illumination optics may produce illumination that is modulated by the fLCOS panel to produce image light. The waveguide may direct the image light towards an eye box. The fLCOS panel may include a ferroelectric liquid crystal (fLC) layer and a backplane. In order to maximize the reflectance of the fLCOS panel and thus the optical performance of the display, the backplane may be a silver backplane or a dielectric mirror backplane. In addition, the backplane may have a cell gap that is equal to a wavelength divided by four times the birefringence of the fLC layer. In order to further optimize the optical performance of the display module, the wavelength used in determining the cell gap may be a green wavelength between 500 nm and 565 nm.

Abstract: Synthetic ?v?6 integrin ligands of Formula I having serum stability and affinity for integrin ?v?6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin ?v?6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include ?v?6 integrin ligands and methods of use are also described.

Abstract: In an embodiment, an electronic device includes a display and processing circuitry. The display includes a plurality of pixels arranged in a plurality of rows, wherein a first grouping of the plurality of rows displays image content during a first portion of an image frame, and wherein a second grouping of the plurality of rows displays image content during a second portion of the image frame. The processing circuitry is operatively coupled to the display and determines a velocity associated with the image content displayed by the first grouping of the plurality of rows moving across the display and adjusts a position of the image content displayed by the second grouping of the plurality of rows during the second portion of the image frame.

Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Superoxide Dismutase 1 (SOD1) gene. The SOD1 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an SOD1 gene. Pharmaceutical compositions that include one or more SOD1 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described SOD1 RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of SOD1 gene expression and a reduction in SOD1 activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including amyotrophic lateral sclerosis (ALS.).

Abstract: Increasing resolution of liquid crystal displays may result in small distances between adjacent liquid crystal display pixels. This tight pixel spacing may reduce transmission through the liquid crystal display pixels and may result in cross-talk between the liquid crystal display pixels. To increase transmission and, correspondingly, display efficiency, a reflective layer may be included in the liquid crystal display. The reflective layer recycles backlight that may otherwise be absorbed, improving transmittance and efficiency. To reduce color shift and color mixing caused by cross-talk, the pixels may have their pixel electrodes arranged in a zigzag layout. Each pixel electrode may have a height that is less than or equal to the total height of the pixel divided by two. The pixel electrodes in a given row are also alternatingly coupled to first and second gate lines. This zigzag layout results in an increased distance between adjacent pixel electrodes, mitigating pixel cross-talk.

Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Superoxide Dismutase 1 (SOD1) gene. The SOD1 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an SOD1 gene. Pharmaceutical compositions that include one or more SOD1 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described SOD1 RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of SOD1 gene expression and a reduction in SOD1 activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including amyotrophic lateral sclerosis (ALS.

Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a double homeobox 4 (DUX4) gene. The DUX4 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a DUX4 gene. Pharmaceutical compositions that include one or more DUX4 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described DUX4 RNAi agents to skeletal muscle cells in vivo, provides for inhibition of DUX4 gene expression and a reduction in DUX4 levels, which can provide a therapeutic benefit to subjects, including human subjects, suffering from certain skeletal muscle-related diseases or disorders including Facioscapulohumeral Muscular Dystrophy (FSID).

Abstract: Synthetic ?v?6 integrin ligands of Formula I having serum stability and affinity for integrin ?v?6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin ?v?6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include ?v?6 integrin ligands and methods of use are also described.